Ministry of Science & Technology
CSIRand Mylan Announce Partnership to identify Advance Therapeutic Options for Management of COVID – 19
Director General of CSIR, Dr. Shehkar C Mande -- “CSIR has prioritized conducting clinical trials of well proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”
The Council of Scientific & Industrial Research , India’s premier research organization, and Mylan Laboratories Limited, the India-based subsidiary of leading global pharmaceutical company Mylan, today announced a partnership to address unmet patient needs amidst the evolving COVID-19 pandemic. Under the partnership, CSIR’s constituent laboratory Indian Institute of Chemical Technology , and Mylan will collaborate to identify potential therapies for COVID-19.
A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration. The first of the clinical trial to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients with mild to moderate COVID -19 at risk of complications.
Director General of CSIR, Dr. Shehkar C Mande stated, “The current collaboration with Mylan is a significant milestone and during the current COVID-19 pandemic, CSIR has prioritized conducting clinical trials of well proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”
Director of CSIR-IICT, Dr Chandrasekhar said, “CSIR is delighted to associate with Mylan as knowledge and scientific partner, and looks forward to working with the company, especially given Mylan’s vast industry experience in clinical trials and commercialization.”
Mylan Chief Operating Officer, Sanjeev Sethi stated, “Our collaboration with CSIR is a strategic step forward aimed at identifying effective treatments for patients with COVID-19. In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can potentially be leveraged in therapies for various other infectious diseases in the future.”
The application for the clinical trials has been submitted to the Drugs Controller General of India  for regulatory approval.
CSIR has appointed Dr. Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director CSIR-IIIM  as a mentor to lead this collaboration.
The Council of Scientific & Industrial Research , known for its cutting-edge R&D knowledgebase in diverse Science & Technology areas, is a contemporary and premier R&D organization. Having a pan-India presence, CSIR has a dynamic network of 38 national laboratories, 39 outreach centres, 3 Innovation Complexes and 5 units. CSIR covers a wide spectrum of science and technology – from oceanography, geophysics, chemicals, drugs, genomics, biotechnology and nanotechnology to mining, aeronautics, instrumentation, environmental engineering and information technology.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. It is one of the world's largest producers of active pharmaceutical ingredients.
(For further information, please contact:
DrGeetha Vani Rayasam
Head- Science Communication and Dissemination
CSIR
Email: gvrayasam@csir.res.in
RitikaVerma
Head of Communications - 
Phone: + 91.40.3086 6419
Email: ritika.verma@mylan.com)